Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical evaluation of noninvasive OCT Angiography using a Zeiss OCT Prototype to replace fluorescein angiography.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optical Coherence Tomography Angiography and in Fluorescein Angiography in Diabetic Retinopathy

NCT05190965

OctA .FFA Findings in DR

UNKNOWN

Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures

NCT01145599

Type 2 Diabetes Non Proliferative Diabetic Retinopathy

COMPLETED

Investigating the Retardation Effect of OCTA-Guided Targeted Photocoagulation on the Progression of Non-Perfusion Areas in Diabetic Retinopathy Patients

NCT06821633

Diabetic Retinopathy

NOT_YET_RECRUITING NA

Macular Involvement in Diabetic Retinopathy Evaluated With Swept-Source OCT

NCT03765112

Diabetes Mellitus Diabetic Retinopathy

UNKNOWN NA

Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus

NCT03422965

Retinal Vascular Retinal Disease Retinal Ischemia +5 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Fluorescein angiography (FA) is the standard and generally accepted method to identify vascular features in the retina, detecting capillary dropout and neovessel growth. Its value is undeniable and is a routine ophthalmological examination. However, it requires intravenous injection of fluorescein, which can cause nausea, vomiting and, rarely, anaphylaxis and death. New OCT angiography methods can detect, noninvasively red blood cells flow and, therefore, identify well the retinal vasculature. It is crucial and of major interest to evaluate the clinical utility of this new methodology comparing this information with the one obtained from fluorescein angiography.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Retinopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients with clinical indication for fluorescein angiography in their clinical practice

Exclusion Criteria

* Subjects with a pacemaker of similarly critical electronic device
* Subjects with severe ocular media opacities
* Subjects with corneal abnormalities

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No